CGP 3466B maleateGAPDH inhibitor CAS# 200189-97-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 200189-97-5 | SDF | Download SDF |
PubChem ID | 9821821 | Appearance | Powder |
Formula | C23H21NO5 | M.Wt | 391.42 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | TCH 346 maleate | ||
Solubility | Soluble to 10 mM in water and to 100 mM in DMSO | ||
Chemical Name | N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine;(Z)-but-2-enedioic acid | ||
SMILES | CN(CC#C)CC1=CC2=CC=CC=C2OC3=CC=CC=C31.C(=CC(=O)O)C(=O)O | ||
Standard InChIKey | SQAZQLMBEHYFJA-BTJKTKAUSA-N | ||
Standard InChI | InChI=1S/C19H17NO.C4H4O4/c1-3-12-20(2)14-16-13-15-8-4-6-10-18(15)21-19-11-7-5-9-17(16)19;5-3(6)1-2-4(7)8/h1,4-11,13H,12,14H2,2H3;1-2H,(H,5,6)(H,7,8)/b;2-1- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Orally active glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor. Exhibits antiapoptotic activity via inhibition of GAPDH nuclear translocation and mitochondrial complex 1-dependent H2O2 release. Displays neuroprotective activity in vivo. |
CGP 3466B maleate Dilution Calculator
CGP 3466B maleate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5548 mL | 12.774 mL | 25.548 mL | 51.096 mL | 63.87 mL |
5 mM | 0.511 mL | 2.5548 mL | 5.1096 mL | 10.2192 mL | 12.774 mL |
10 mM | 0.2555 mL | 1.2774 mL | 2.5548 mL | 5.1096 mL | 6.387 mL |
50 mM | 0.0511 mL | 0.2555 mL | 0.511 mL | 1.0219 mL | 1.2774 mL |
100 mM | 0.0255 mL | 0.1277 mL | 0.2555 mL | 0.511 mL | 0.6387 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
R-(2)-Deprenyl represents one of the drugs currently used for the treatment of Parkinson’s disease. The mechanism of action of neuroprotection as well as inhibition of apoptosis remains elusive. CGP 3466 is a structurally related R-(2)-deprenyl analoge that exhibits virtually no monoamine oxidase type B inhibiting activity but is neuroprotective.
In vitro: CGP 3466B is structurally related to both classical monoamine oxidase inhibitors and tricyclic antidepressent agents but lacks the pharmacological properties relevant to their anti-depressant effects. CGP 3466B has been shown to rescue human neuroblastoma and PC-12 cells from apoptotic death and also cerebellar granule cells in vitro from death induced by cytosine arabinoside [1].
In vivo: In pmn/pmn mice, CGP 3466B was administered orally at the onset of the clinical symptoms (2 weeks after birth). CGP 3466B slowed disease progression as determined by a 57% life-span increase, preservation of body weight and motor performance. The data support evaluation of CGP 3466B as a potential motor neuron disease treatment [2].
Clinical trial: Up to now, CGP 3466B is still in the preclinical development stage.
References:
[1] Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van Oostrum J, Waldmeier P, Furst P. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem. 1998 Mar 6;273(10):5821-8.
[2] Sagot Y, Toni N, Perrelet D, Lurot S, King B, Rixner H, Mattenberger L, Waldmeier PC, Kato AC. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br J Pharmacol. 2000 Oct;131(4):721-8.
- Fmoc-Arg(Pbf)-OPfp
Catalog No.:BCC3041
CAS No.:200132-16-7
- Dehydrochromolaenin
Catalog No.:BCN4072
CAS No.:20013-76-7
- Pyrocurzerenone
Catalog No.:BCN4067
CAS No.:20013-75-6
- Isoscoparin
Catalog No.:BCN7845
CAS No.:20013-23-4
- Caulophylline hydriodide
Catalog No.:BCC8141
CAS No.:20013-22-3
- 3'-Methoxydaidzin
Catalog No.:BCN7720
CAS No.:200127-80-6
- Boc-Arg(Pbf)-OH
Catalog No.:BCC3066
CAS No.:200124-22-7
- SKF 38393 hydrobromide
Catalog No.:BCC6848
CAS No.:20012-10-6
- H-D-Arg(Pbf)-OH
Catalog No.:BCC2872
CAS No.:200116-81-0
- H-Arg(Pbf)-OH
Catalog No.:BCC2866
CAS No.:200115-86-2
- Valinomycin
Catalog No.:BCC7671
CAS No.:2001-95-8
- Benzyl 4-bromophenyl ketone
Catalog No.:BCC8868
CAS No.:2001-29-8
- Z-Arg(Pbf)-OH.CHA
Catalog No.:BCC3064
CAS No.:200190-89-2
- Melanocyte stimulating hormone release inhibiting factor
Catalog No.:BCC1043
CAS No.:2002-44-0
- Boc-D-Asp(OtBu)-OH.DCHA
Catalog No.:BCC3373
CAS No.:200334-95-8
- Fmoc-D-Asp(OtBu)-Opfp
Catalog No.:BCC3472
CAS No.:200335-75-7
- Fmoc-D-Cit-OH
Catalog No.:BCC3181
CAS No.:200344-33-8
- Fmoc-D-Cys(Trt)-OPfp
Catalog No.:BCC3482
CAS No.:200395-72-8
- 6-Chloroguanine riboside
Catalog No.:BCC8771
CAS No.:2004-07-1
- UB 165 fumarate
Catalog No.:BCC5746
CAS No.:200432-86-6
- Picralinal
Catalog No.:BCN4878
CAS No.:20045-06-1
- GMX1778 (CHS828)
Catalog No.:BCC6527
CAS No.:200484-11-3
- Hotrienol
Catalog No.:BCN6340
CAS No.:20053-88-7
- Fmoc-D-Glu(OtBu)-OPfp
Catalog No.:BCC3497
CAS No.:200616-21-3
Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors.[Pubmed:30351952]
J Proteome Res. 2018 Nov 5.
Liquid chromatography mass spectrometry (LCMS) proteomic analyses have revealed that host proteins are often captured in extracellular virions. These proteins may play a role in viral replication or infectivity and can represent targets for broad-spectrum antiviral agent development. We utilized LCMS to determine the host protein composition of Lassa virus-like particles (LASV VLPs). Multiple host proteins incorporated in LASV VLPs are also incorporated in unrelated viruses, notably ribosomal proteins. We assembled a data set of host proteins incorporated into extracellular viral particles. The frequent incorporation of specific host proteins into viruses of diverse families suggests that interactions of these proteins with viral factors may be important for effective viral replication. Drugs that target virion-associated host proteins could affect the protein in the extracellular virion or the host cell. Compounds that target proteins incorporated into virions with high frequency, but with no known antiviral activity, were assayed in a scalable viral screening platform, and hits were tested in competent viral systems. One of these molecules, GAPDH modulating small molecule CGP 3466B maleate (Omigapil), exhibited a dose-dependent inhibition of HIV, dengue virus, and Zika virus.
Clorgyline and other propargylamine derivatives as inhibitors of succinate-dependent H(2)O(2) release at NADH:UBIQUINONE oxidoreductase (Complex I) in brain mitochondria.[Pubmed:18763029]
J Bioenerg Biomembr. 2008 Aug;40(4):289-96.
Complex I is the main O(2)(-) producer of the mitochondrial respiratory chain. O(2)(-) release is low with NAD-linked substrates and increases strongly during succinate oxidation, which increases the QH(2)/Q ratio and is rotenone sensitive. We show that the succinate dependent O(2)(-) production (measured as H(2)O(2) release) is inhibited by propargylamine containing compounds (clorgyline, CGP 3466B, rasagiline and TVP-1012). The inhibition does not affect membrane potential and is unaffected by DeltapH modifications. Mitochondrial respiration is similarly unaffected. The propargylamines inhibition of O(2)(-)/H(2)O(2) production is monitored also in the presence of the Parkinson's disease toxin dopaminochrome which stimulates O(2)(-) release. Propargylamine-containing compounds are the first pharmacological inhibitors described for O(2)(-) release at Complex I.
TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates.[Pubmed:14572443]
Neurobiol Dis. 2003 Nov;14(2):205-17.
The neuroprotective efficacy of the propargylamine TCH346 was studied in the primate model of Parkinson's disease, the bilaterally MPTP-treated monkey. Male rhesus monkeys received 2.5 mg MPTP into the left carotid artery and, 8 weeks later, 1.25 mg MPTP into the right carotid artery. Starting 2 h after the second MPTP infusion, either 0.014 mg/kg TCH346 or its solvent was subcutaneously injected twice per day for 14 days. The first MPTP treatment induced mild Parkinson symptoms, reduced right limb movements, and reduced FDOPA uptake in the left striatum. The second MPTP treatment made Parkinson symptoms worse, reduced left limb movements, and reduced FDOPA uptake in the right striatum of solvent-treated monkeys. In contrast, the second MPTP treatment did not further worsen motor symptoms and did not decrease FDOPA uptake in the right striatum of TCH346-treated monkeys. Although the effects of the second MPTP treatment were largely prevented, the effects of the first MPTP treatment were not reversed by TCH346. Immunohistochemical examination confirmed the dramatic loss of dopamine cells in vehicle-treated monkeys and the preservation of these neurons in the right brain side of the TCH346-treated animals. In conclusion, systemic administration of TCH346 prevented motor symptoms and nigrostriatal degeneration induced by MPTP in primates.
An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease.[Pubmed:11030721]
Br J Pharmacol. 2000 Oct;131(4):721-8.
Apoptosis and mitochondrial dysfunction are thought to be involved in the aetiology of neurodegenerative diseases. We have tested an orally active anti-apoptotic molecule (CGP 3466B) that binds to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in an animal model with motoneuron degeneration, i.e. a mouse mutant with progressive motor neuronopathy (pmn). In pmn/pmn mice, CGP 3466B was administered orally (10 - 100 nmol kg(-1)) at the onset of the clinical symptoms (2 weeks after birth). CGP 3466B slowed disease progression as determined by a 57% increase in life-span, preservation of body weight and motor performance. This improvement was accompanied by a decreased loss of motoneurons and motoneuron fibres as well as an increase in retrograde transport. Electron microscopic analysis showed that CGP 3466B protects mitochondria which appear to be selectively disrupted in the motoneurons of pmn/pmn mice. The data support evaluation of CGP 3466B as a potential treatment for motor neuron disease.